Verona Pharma plc

Verona Pharma — Merger or Acquisition (July 2025)

25 slides from Verona Pharma's merger presentation, Jul 9, 2025

  1. Slide 1: Acquisition of Verona Pharma

    Acquisition of Verona Pharma Merck & Co., Inc., Rahway, N.J., USA July 9, 2025

  2. Slide 2: Important information about the transaction

    Important information about the transaction Important Information and Where to Find it In connection with the proposed acquisition of Verona Pharma plc (“Verona Pharma”) by a subsidiary of Merck & Co., Inc. (“Merck”), Verona Pharma will file with the Securities and Exchange Commission (“SEC”) a prox

  3. Slide 3: Forward-looking statements

    Forward-looking statements This presentation of Merck & Co., Inc., Rahway, N.J., USA ((or the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including with respect to Merck’s proposed acq

  4. Slide 4: Agenda

    Agenda Rob Davis Chairman & Chief Executive Officer Strategic Rationale | Rob Davis Dr. Dean Li Scientific Overview | Dr. Dean Li President, Merck Research Laboratories Commercial Opportunity | Jannie Oosthuizen Jannie Oosthuizen Financial Overview | Caroline Litchfield President, Human Health U.S.

  5. Slide 5: Strategic Rationale

    Strategic Rationale Rob Davis Chairman & Chief Executive Officer

  6. Slide 6: Merck continues to advance science-led strategy through acquisition of Verona Pharma

    Merck continues to advance science-led strategy through acquisition of Verona Pharma Science-driven business development that strengthens and complements cardio-pulmonary portfolio Ohtuvayre® is the first novel inhaled COPD maintenance treatment in more than 20 years, a large disease area with signi

  7. Slide 7: Scientific Overview

    Scientific Overview Dr. Dean Li President, Merck Research Laboratories

  8. Slide 8: Substantial unmet need remains for people with COPD

    Substantial unmet need remains for people with chronic obstructive pulmonary disease (COPD) COPD manifests as chronic bronchitis and/or COPD is a major driver of morbidity and mortality emphysema, both of which limit airflow into and worldwide out of the lungs Symptoms include dyspnea, chronic cough

  9. Slide 9: Ohtuvayre is the first inhaled COPD maintenance treatment combining bronchodilatory and anti-inflammatory activity

    Ohtuvayre® is the first inhaled COPD maintenance treatment that combines bronchodilatory and non-steroidal anti-inflammatory activity Ohtuvayre® is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) ‒ First novel inhaled mechanism for maintenance treatment of COPD in more

  10. Slide 10: Ohtuvayre demonstrated improvement in lung function in two Phase 3 trials

    Ohtuvayre® demonstrated clinically meaningful improvement in lung function regardless of background therapy in two Phase 3 trials 1 Statistically significant improvement of +87 mL and +94 mL in average FEV AUC from baseline versus placebo 1 0-12h 12-Hour Serial FEV Profile at Week 12 1 ENHANCE-1 ENH

  11. Slide 11: Pooled data reduced annualized exacerbation rate in ENHANCE-1 and ENHANCE-2

    Pooled data reduced the annualized moderate or severe exacerbation rate over 24 weeks in ENHANCE-1 and ENHANCE-2 ENHANCE-1 ENHANCE-2 Annualized Annualized Exacerbation Exacerbation Event Rate Rate Ratio Event Rate Rate Ratio Treatment Rate p-value Treatment Rate p-value LS mean, (95% CI) LS mean, (9

  12. Slide 12: ENHANCE studies demonstrated positive benefit-risk profile

    ENHANCE-1 and ENHANCE-2 studies demonstrated positive benefit-risk profile of Ohtuvayre® ENHANCE-1 & ENHANCE-2 Pooled 24-Week Safety Population Urinary tract Treatment Back pain Hypertension Diarrhea Safety data demonstrated positive benefit-risk infection profile Ensifentrine 3 mg 18 (1.8%) 17 (1.7

  13. Slide 13: Pipeline provides additional potential indications and product opportunities

    Pipeline provides additional potential indications and product opportunities Approved / Product Indication Pre-clinical Phase 1 Phase 2 Phase 3 Available Maintenance treatment of COPD Non-Cystic Fibrosis bronchiectasis Ensifentrine (Nebulizer) Cystic Fibrosis Asthma Ensifentrine + Maintenance LAMA (

  14. Slide 14: Advancing Phase studies that could further patient benefit

    Advancing Phase 2 studies that could further patient benefit Non-cystic fibrosis bronchiectasis Ensifentrine + LAMA (glycopyrrolate) Chronic disease marked by recurrent infection and Combines two bronchodilator mechanisms with progressive lung damage non-steroidal anti-inflammatory effects Ohtuvayre

  15. Slide 15: Commercial Opportunity

    Commercial Opportunity Jannie Oosthuizen President, Human Health U.S.

  16. Slide 16: Significant unmet medical need remains in COPD

    Significant unmet medical need remains in COPD Approximately 8.6M patients on maintenance therapy in the U.S. ‒ ~50% remain persistently symptomatic COPD is a progressive 2 ‒ Estimated direct and indirect costs of ~$50B , driven disease and the mostly by hospitalizations th COPD significantly impact

  17. Slide 17: Ohtuvayre is a first-in-class novel mechanism with a broad label

    Ohtuvayre® is a first-in-class novel mechanism with a broad label for the maintenance treatment of COPD in adults First and only product to combine bronchodilation and non-steroidal anti-inflammatory properties in one molecule Recommended in GOLD guidelines 1 LAMA, LABA LABA + LAMA LABA + LAMA Curre

  18. Slide 18: Significant opportunity to benefit patients with COPD

    1,2 Significant opportunity to benefit patients with COPD ~8.6M 3 Maintenance Treated COPD Patients ~50% Persistently Symptomatic COPD Patients 2 Regardless of Therapy Launch Focus ~4.3M Persistently Symptomatic Patients 18 1. Chen, et al., Int J Chron Obstruct Pulmon Dis. 2018;13:1365-1376 2. Phree

  19. Slide 19: Strong initial commercial launch with rapid increases across key metrics

    Strong initial commercial launch with rapid increases across key metrics 1Q25: >25% ~5.3K $71.3M growth in new patient starts prescribers since launch (vs. 4Q24) ~25K ~50% prescriptions dispensed increase in prescribers (vs. 4Q24) $36.6M ~60% >425 $5.6M prescriptions dispensed were prescribers have

  20. Slide 20: Ohtuvayre represents a multibillion dollar commercial opportunity into the mid-2030s

    To be updated Ohtuvayre® represents a multibillion dollar commercial opportunity into the mid-2030s COPD therapy market is large and growing Potential to be preferred maintenance therapy for persistently symptomatic patients Expect continued strong uptake by physicians and patients, enabled by favor

  21. Slide 21: Financial Overview

    Financial Overview Caroline Litchfield Chief Financial Officer

  22. Slide 22: Financial overview of Verona Pharma acquisition

    To be updated Financial overview of Verona Pharma acquisition • Merck has agreed to acquire all outstanding shares of Verona Pharma for a purchase price of $107 per ADS • Total transaction value of ~$10 billion (~$9.8 billion net of ~$200 million of cash and investments and debt) Transaction Details

  23. Slide 23: Q&A

    Q&A Rob Davis Caroline Litchfield Chairman & Chief Chief Financial Officer Executive Officer Dr. Dean Li Peter Dannenbaum President, SVP, Investor Relations Merck Research Laboratories Jannie Oosthuizen President, Human Health U.S.

  24. Slide 24: Appendix

    Appendix 24

  25. Slide 25: Acronyms

    Acronyms ADS = American depository share cAMP = Cyclic adenosine monophosphate COPD = Chronic obstructive pulmonary disease cGMP = Cyclic guanosine monophosphate CI = Confidence interval DPI = Dry powder inhaler ICS = Inhaled corticosteroids LABA = Long-acting beta agonist LAMA = Long-acting muscari

Verona Pharma — Merger or Acquisition (July 2025) on 6ix